newsfilter
← Earnings
Earnings Releases·

Corbus Pharmaceuticals — Q3 2026 Earnings Summary

  • Reported a net loss of $37.8 million ($1.81/share) for Q3 2026, an improvement from $23.3 million ($1.90/share) in Q3 2025, driven by a $15.0 million development milestone payment that increased operating expenses to $38.8 million.
  • Initiated dosing in the registrational TEMPO-1 Phase 3 trial for sutantatug envedotin (CRB-701) in September 2026, while CANYON-1 Phase 1b data for CRB-913 showed 5% mean weight loss at 12 weeks with a favorable safety profile.
  • Cash, cash equivalents, and investments totaled $115.3 million as of September 30, 2026, sufficient to fund operations into 2028; total assets decreased to $122.9 million from $168.2 million at year-end 2025.
  • Plans to present late-breaking CANYON-1 data at ObesityWeek® 2026 on November 15, 2026, and report sutantatug envedotin combination data in first-line oropharyngeal cancer in Q1 2027 to support registration-enabling trials.
  • Appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer in August 2026; weighted average shares outstanding increased to 20.8 million in Q3 2026 from 12.3 million in the prior year period.
Company
CORBUS PHARMACEUTICALS HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology